Covid19 Clinical Trial - Neurodegeneration Markers & Neurological Course

Status Terminated

Clinical Trial Summary

Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature of coronavirus infection in animals, the investigators examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection.

Clinical Trial Description

In animals, coronavirus infection is commonly associated with CNS involvement: epilepsy and ataxia are observed during Feline Infectious Peritonitis (FIP) and virus is recovered in CSF, CNS is involved with strain-dependent severity in mice and rats infected by murine hepatitis virus, and murine infection with MHV A59 strain is a model of multiple sclerosis (MS). Mice encephalitis occurs through infection of olfactory bulb and spreads along the axonal pathway. Viral antigens and neuronal apoptosis are observed in brainstem and hypothalamus, without minimal or absent inflammation. Most COVID-19 patients with neurologic impairment displayed expected complications of severe infections (e.g. neuropathy and muscle loss, stroke) but encephalitis remained exceptional, as previously observed in SRAS. It is argued that central lesions may explain some of the clinical features ventilation failure, or disproportionate residual fatigue and cognition impairment in survivors of severe COVID infection. According to data obtained from various coronavirus infections in animals, the investigators ask if severe COVID infection in human could be associated with sub-clinical encephalitis. This clinical trial examines highly sensitive blood biomarkers of brain dysfunction in correlation with late clinical outcome. Biomarkers are neurofilament light chain (NFL) and GFAP. Clinical outcomes are death, signs of central neurologic sequellae, and fatigue. Clinical examination and blood samples will be obtained at inclusion (d0), which is mostly the entrance in intensive care unit (ICU), at day 7 (between day 4 and exit from ICU) and at day 60. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04361344
Study type	Interventional
Source	Centre Hospitalier de PAU
Contact
Status	Terminated
Phase	N/A
Start date	May 19, 2020
Completion date	October 25, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04997551` - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19	Phase 3
Recruiting	`NCT04977024` - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer	Phase 2
Completed	`NCT05049226` - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated	`NCT04455815` - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)	Phase 2
Completed	`NCT04662437` - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Recruiting	`NCT05792878` - Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Completed	`NCT04659200` - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting	`NCT04470583` - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn	`NCT04377568` - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children	Phase 2
Completed	`NCT04848610` - The Factors That Affect the Infection of COVID-19
Recruiting	`NCT04582903` - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Recruiting	`NCT06032000` - Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)	Phase 1
Terminated	`NCT04941703` - "CHANGE COVID-19 Severity"	Phase 1/Phase 2
Active, not recruiting	`NCT04639466` - A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection	Phase 1/Phase 2
Completed	`NCT04575038` - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19	Phase 2
Recruiting	`NCT05022446` - The Impact of COVID-19 on Pulmonary Procedures
Completed	`NCT04347798` - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting	`NCT04650178` - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting	`NCT04169542` - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection — MARNEVO-Covid

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms